ASCO 2025 Chicago
Representing Slovakia at the World’s Largest Oncology Conference – ASCO 2025, Chicago
MultiplexDX International is proud to represent Slovakia at ASCO 2025 in Chicago, the world’s largest oncology conference. Our delegation, comprising David Eberhard (Chief Medical Officer), Evan Paul (Chief Scientific Officer), and Rolando Brawer (Chief Commercial Officer), is engaging with the global oncology community, which includes leading oncologists, pathologists,researchers, innovative companies, and other experts.
We have already participated in numerous productive meetings, discussions, lectures, working lunches, and business dinners. Our breast cancer diagnostic test has gained recognition within the professional community and carries significant expectations. The focus of our conversations and collaborations at ASCO centers on confirming its potential through ongoing and upcoming clinical studies.
We are confident in our ability to demonstrate that Slovak innovations can save lives on a global scale.We are deeply grateful for the support and collaboration that make this possible.
From Chicago, we send our warmest regards back home to Slovakia!
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
